Compare Moderna, Inc. (MRNA) vs Roundhill NVDA WeeklyPay ETF (NVDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Roundhill NVDA WeeklyPay ETF — how do they compare? Moderna, Inc. trades at $63.62 (market cap $24.18B), while Roundhill NVDA WeeklyPay ETF trades at $38.32. The key difference: Moderna, Inc. is trading nearer its 52-week high, Roundhill NVDA WeeklyPay ETF nearer its low. Which is the better fit depends on your goals.
| MRNA | NVDW | |
|---|---|---|
Market Cap | $24.18B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $81.80 | $52.59 |
52-Week Low | $22.36 | $31.88 |
Enterprise Value | $20.33B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.
The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.
NVDW trades at $38.58, up 3.35% today with a bullish technical signal supported by moving averages. The stock shows strong momentum with key indicators suggesting mild overbought conditions. Recent dividend activity indicates consistent shareholder returns, though financial ratios remain undisclosed pending updated filings.
Outlook remains positive given technical strength and dividend consistency, but limited fundamental data requires caution. Key risks include dependency on underlying NVDA performance and payout volatility. Investors should await comprehensive financial disclosures for full valuation assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Roundhill NVDA WeeklyPay ETF
NVDW is an actively managed ETF that seeks to provide weekly distributions and returns equal to 1.2 times (120%) the calendar week performance of Nvidia (NVDA) common shares. It combines modest leverage with a high-frequency payout schedule, designed for investors who want amplified exposure to Nvidia alongside a consistent weekly income stream.
Read more on NVDW →
